[Effectiveness and safety of amlodipine in secondary prevention in patients with myocardial infarction].
Amlodipin (norvask) effectiveness was studied in 18 patients who survived primary Q-myocardial infarction. The 2-year treatment produced a positive effect in 66.6% patients, a negative one--in 11.1%. One patient died, a repeat non-fatal MI developed in 2 patients. Complications were registered in 1 patient. The drug reduced the number of angina attacks, amount of nitroglycerin (by 46.6 and 45.5%, respectively), the tolerance increased by 26.7, cardiac performance by 59.9%. It also led to a fall of both systolic and diastolic blood pressure (by 14.0 and 9.9%, respectively). Heart rate remained unchanged. Left ventricle underwent adaptive remodeling, myocardial ischemia diminished in the number of episodes and their duration. Frequent atrial and rare ventricular extrasystole disappeared in 1 patient.
Bichan
N A
NA
Tepliakov
A T
AT
D000328:Adult; D017311:Amlodipine / Q000009:adverse effects / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D016896:Treatment Outcome
D002121:Calcium Channel Blockers; D017311:Amlodipine